IFNG and hemophagocytic syndrome: If refractory can consider the addition of etoposide, which is the typical treatment for malignancy-related HLH [6], then for HLH, treatment is adapted to the underlying condition and severity and for refractory cases can consider agents such as anakinra (IL-1 inhibitor), emapalumab (IFN-γ inhibition), and ruxolitinib (JAK inhibitor) [7].